As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Vigil Neuroscience, Inc. The largest reported stake is Glazer Capital, LLC's, at 6.45%. 4 filings are on record since August 7, 2025 (Schedule 13G/A, August 14, 2025).
Sell to companies like Vigil Neuroscience, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Beryl Capital Management LLC · Percent: 0% · SCHEDULE 13G/A
- · Holder: Biotechnology Value Fund L P · Percent: 0% · SCHEDULE 13G/A
- · Holder: Glazer Capital, LLC · Percent: 6.45% · SCHEDULE 13G/A
- · Holder: Atlas Venture Fund XII, L.P. · Percent: 0% · SCHEDULE 13D/A
Vigil Neuroscience, Inc. has 4 Schedule 13D or 13G filings on record since 2025-08-07. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Glazer Capital, LLC | 6.45% | 3,012,068 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Atlas Venture Fund XII, L.P. | 0% | 0 | SCHEDULE 13D/A, 2025-08-07 | 2025-08-05 |
| Biotechnology Value Fund L P | 0% | 0 | SCHEDULE 13G/A, 2025-08-14 | 2025-06-30 |
| Beryl Capital Management LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Vigil Neuroscience, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Vigil Neuroscience, Inc. and the records around it.
Companies that share a holder
- Beryl Capital Management LLC also filed stake reports on 4 other companies: Y-mAbs Therapeutics, Inc. (Nov 2025)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
- Glazer Capital, LLC also filed stake reports on 107 other companies: Bumble Inc (Oct 2026), Weave Communications Inc (Oct 2026), Utz Brands Inc (Oct 2026)
Watch Vigil Neuroscience, Inc.
Get an email when Vigil Neuroscience, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Vigil Neuroscience, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vigil Neuroscience, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vigil Neuroscience, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
4 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Atlas Venture Fund XII, L.P.
Item 4 of the Statement is hereby amended and supplemented as follows: On May 21, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Sanofi, a French societe anonyme ("Parent" or "Sanofi"), and Vesper Acquisition Sub Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"), pursuant to which, Merger Sub would merge with and into the Issuer (the "Merger"), with the Issuer surviving the merger as a wholly-owned subsidiary of Parent. On August 4, 2025, at a special meeting of stockholders of the Issuer, the Issuer's stockholders voted to adopt the Merger Agreement. On August 5, 2025, the Merger closed and each share of the Issuer's Common Stock issued and outstanding, including all of the shares of Common Stock owned by the Reporting Persons, was converted into the right to receive (i) $8.00 per share of Common Stock in cash, without interest plus (ii) one contingent value right, representing the right to receive $2.00 payable in cash, conditioned upon satisfaction of a certain clinical milestone.Item 4 of the SCHEDULE 13D/A filed 2025-08-07
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-07 | Atlas Venture Fund XII, L.P. | 0% | SCHEDULE 13D/A |
| 2025-08-14 | Biotechnology Value Fund L P | 0% | SCHEDULE 13G/A |
| 2025-08-14 | Glazer Capital, LLC | 6.45% | SCHEDULE 13G/A |
| 2025-11-14 | Beryl Capital Management LLC | 0% | SCHEDULE 13G/A |
Questions about who owns Vigil Neuroscience, Inc.
Who owns Vigil Neuroscience, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Vigil Neuroscience, Inc.: Glazer Capital, LLC (6.45%, Schedule 13G/A, filed 2025-08-14).
When did Glazer Capital, LLC buy into Vigil Neuroscience, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Glazer Capital, LLC on this page is the Schedule 13G/A, filed 2025-08-14, reporting 6.45%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 4 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for Vigil Neuroscience, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.